Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission to Nana-val for the Treatment of Diffuse Large B-cell LymphomaGlobeNewsWire • 01/19/23
Viracta Therapeutics Announces First Clinical Response in Epstein-Barr Virus-Positive (EBV+) Solid Tumor Setting and Outlines Key 2023 Clinical ObjectivesGlobeNewsWire • 01/08/23
Viracta Therapeutics Announces Preliminary Dose-Ranging Data from the Phase 1b/2 Trial of Nana-val in Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors at the ESMO Immuno-Oncology CongressGlobeNewsWire • 11/30/22
Viracta Therapeutics Reports Third Quarter 2022 Financial Results and Provides Updates on Clinical ProgramsGlobeNewsWire • 11/10/22
Viracta Therapeutics Announces Chief Executive Officer Leadership Succession to Drive the Next Phase of the Company's Strategic Development and GrowthPRNewsWire • 09/19/22
Does Sunesis (VIRX) Have the Potential to Rally 335% as Wall Street Analysts Expect?Zacks Investment Research • 09/09/22
Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission for Nana-val for the Treatment of Peripheral T-cell LymphomaPRNewsWire • 09/07/22
Viracta Therapeutics Chief Scientific Officer, Dr. Ayman Elguindy, Elected to the Governing Board of the International Association for Research on Epstein-Barr Virus and Associated DiseasesPRNewsWire • 08/16/22
Viracta Therapeutics Reports Second Quarter 2022 Financial Results and Recent UpdatesPRNewsWire • 08/09/22
Viracta Therapeutics President and Chief Executive Officer Dr. Ivor Royston Receives the Science History Institute's Biotechnology Heritage AwardPRNewsWire • 06/13/22
Viracta Therapeutics Provides an Update on the Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and Announces Upcoming Poster Presentation at the ASCO Annual MeetingPRNewsWire • 06/02/22
Viracta Therapeutics Reports First Quarter 2022 Financial Results and Recent UpdatesPRNewsWire • 05/10/22
Viracta Therapeutics to Present at the 21st Annual Needham Virtual Healthcare ConferencePRNewsWire • 04/07/22
Viracta Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare ConferencePRNewsWire • 03/09/22
Viracta Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare ConferencePRNewsWire • 02/10/22
Viracta Therapeutics Announces First Patient Dosed in Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive Solid TumorsPRNewsWire • 01/31/22
Viracta Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual ConferencePRNewsWire • 01/04/22
Viracta Therapeutics Presents Preclinical Vecabrutinib Data in Oral and Poster Presentations at ASH 2021PRNewsWire • 12/14/21